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Background: This study investigated the correlation of lipoprotein-associated phospholipase A2
(Lp-PLA2) levels with angiographic coronary artery disease, the extent of angiographic coronary artery
lesions and coronary artery disease risk factors in the elderly.
Methods: Plasma Lp-PLA2, lipid, and high-sensitivity C-reactive protein levels were measured in 192
elderly patients who underwent coronary angiography because of suspected coronary artery disease. The
extent of coronary artery lesions was recorded according to the number of vessels with lesions and the
Gensini score system. The relationships of Lp-PLA2 with angiographic coronary artery disease, the extent
of coronary artery lesions, and associated risk factors were assessed.
Results: Plasma Lp-PLA2 (359.56 ± 133.47 mg/L vs. 215.12 ± 58.93 mg/L, p < 0.001), triglycerides
(1.87 ± 1.29mM vs. 1.23 ± 0.53mM, p < 0.001), total cholesterol (4.47 ± 0.69mM vs. 3.59 ± 0.75mM,
p < 0.01), low-density lipoprotein cholesterol (2.52 ± 0.91mM vs. 2.10 ± 0.63mM, p < 0.01), and
C-reactive protein (7.57 ± 1.82 mg/L vs. 2.65 ± 1.74 mg/L, p < 0.05) were signiﬁcantly higher in the
angiographic coronary artery disease group compared to the controls. Lp-PLA2 increased slightly but
not signiﬁcantly with an increasing number of coronary artery lesions and Gensini score. Spearman
correlation analysis revealed that Lp-PLA2 is positively correlated with age (r ¼ 0.249, p < 0.05), total
cholesterol (r ¼ 0.326, p < 0.01), and low-density lipoprotein cholesterol (r ¼ 0.265, p < 0.05). Multi-
variate logistic regression analysis showed that Lp-PLA2 [odds ratio, 1.03 (1.01e1.06), p < 0.05] and total
cholesterol [odds ratio, 2.74 (1.84e7.80), p < 0.05] are independent predictors for angiographic coronary
artery disease.
Conclusion: Lp-PLA2 was conﬁrmed as a risk factor for coronary artery disease and independently pre-
dicts the presence of angiographic coronary artery disease in the elderly.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Atherosclerosis is highly complex and modulated by numerous
genetic and environmental risk factors. The traditional risk
factors cannot explain all coronary events. Inﬂammation underlinesre that they have no conﬂicts
Renmin Road, Department of
South University, Changsha,
. Zhang).
tric Emergency & Critical Care Meboth the onset and progression of atherosclerosis. Serum markers
of inﬂammation are involved in plaque initiation, formation
and rupture1e3. Recently, considerable attention has been paid to
lipoprotein-associated phospholipase A2 (Lp-PLA2), which is pro-
duced by inﬂammatory cells and binds to low-density lipoprotein
cholesterol (LDL-C) and other lipoproteins4. It has been considered
as a new inﬂammatory marker and proposed to be more speciﬁc
to vascular inﬂammation. Now, a preponderance of evidence has
demonstrated a proatherogenic function for this enzyme, high-
lighted its importance in promoting atherosclerosis, and shown
that it is an independent predictor of coronary artery disease (CAD).
Elevated Lp-PLA2 is associated with an increased risk of CAD5 and adicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics and lipoprotein-associated phospholipase A2 levels in the
coronary artery disease (CAD) and control groups.
CAD (n ¼ 124) Control (n ¼ 68)
Age (y) 72 ± 13 72 ± 12
Sex (male/female) ratio 101/23 55/13
BMI (kg/m2) 24.39 ± 3.14 24.33 ± 3.48
Hypertension 63 (50.80) 32 (47.05)
Diabetes 22 (17.74) 10 (14.71)
Current smoking 28 (22.58) 12 (17.64)
TC (mM) 4.47 ± 0.69** 3.59 ± 0.75
LDL-C (mM) 2.52 ± 0.91** 2.10 ± 0.63
HDL-C (mM) 1.12 ± 0.33 1.10 ± 0.32
TG (mM) 1.87 ± 1.29*** 1.23 ± 0.53
hs-CRP (mg/L) 7.57 ± 1.82* 2.65 ± 1.74
Lp-PLA2 (mg/L) 359.56 ± 133.47*** 215.12 ± 58.93
Data are presented as n (%) or mean ± SD.
*p < 0.05, **p < 0.01, and ***p < 0.001 compared to the control.
BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; hs-
CRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein
cholesterol; Lp-PLA2 ¼ lipoprotein-associated phospholipase A2; TC ¼ total
cholesterol.
Lp-PLA2 Associated with Angiographic CAD 83higher incidence of major adverse events at follow-up6e8. However,
Lp-PLA2 levels in the elderly with CAD remain poorly investigated.
A few studies have demonstrated that, in the elderly, Lp-PLA2 and
other inﬂammatory indices are potential biomarkers for vascular
events, particularly CAD9e11. To the best of our knowledge, there is
no study on the relationship between Lp-PLA2 and angiographic
CAD in elderly patients. This study aimed to evaluate the correla-
tions between Lp-PLA2 and angiographic CAD, the extent of
angiographic coronary artery lesions and CAD risk factors in the
elderly.
2. Methods
2.1. Participants
The study included 192 consecutive patients older than
60 years, undergoing diagnostic coronary angiography at our hos-
pital because of suspected CAD. All of the data regarding these
patients were recorded in a structured manner that included the
patients' demographic, clinical, and investigational parameters. The
case notes of these patients were reviewed, and information
regarding their demography, disease duration, clinical manifesta-
tions, radiological features, and treatment (medical, surgical, and
interventional therapy) were retrieved. These data were system-
atically entered into a Microsoft Excel chart. The study was
approved by the Second Xiangya Hospital of Central South Uni-
versity Review Board, and informed written consent was obtained
from each participant. Patients were excluded if they suffered
from hepatic or renal failure, rheumatic heart disease, cardiomy-
opathy, acute or chronic infection, malignancy, autoimmune dis-
ease, or connective tissue disease.
2.2. Blood collection and biochemical analyses
Venous blood was drawn from all patients under standardized
conditions after a 12-hour fast before coronary angiography was
performed. Serum samples were collected within 30 minutes and
centrifuged at 3000 g for 10minutes. Serum triglycerides (TG), total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-
C, high-sensitivity C-reactive protein (hs-CRP), fasting blood
glucose, liver function, and renal function were measured using
standard automated enzymatic methods on a Hitachi 912 auto-
mated analyzer, using reagents from Kamiya Biomedical Company
(Seattle, WA, USA).
2.3. Measurement of Lp-PLA2 levels
Arterial blood was collected in EDTA-treated tubes. Plasma
samples were divided into aliquots and stored at 80C for mea-
surement. Lp-PLA2 levels were determined using enzyme-linked
immunosorbent assay (Catalogue No. E0867h; ADL, San Diego,
CA, USA) according to the manufacturer's instructions. The sensi-
tivity of the test kit was 1.0 mg/L. All samples were measured in
duplicate and in a blinded fashion.
2.4. Angiographic analysis and lesion assessment
Right and left coronary angiographies were performed for each
patient. Quantitative analysis of left ventricular function and cor-
onary lesions were determined using a digital imaging system. The
coronary angiograms were read by two experienced technicians
blinded to patient identity, clinical diagnosis, and the study. Diag-
nosis of CAD was according to the following coronary angiographic
analysis: no less than 50% luminal diameter stenosis either in the
left main, left anterior descending, left circumﬂex, or right coronaryartery. Patients without CAD were deﬁned as having <50% stenosis
in all segments. Patients (n ¼ 192) were divided into the CAD
(124 cases) and control (68 cases) groups based on coronary angi-
ography. The extent of CAD was quantiﬁed: (1) number of the
three major coronary arteries with stenosis >50% (1-, 2-, and 3-
vessel disease groups), with the left main counting as 2 vessels; and
(2) Gensini score12 [low-score (<20), intermediate-score (20e40),
and high-score (40) groups]. The CAD assessment was performed
blinded to the results of the blood testing.
2.5. Assessment of other parameters
Information about medical history, medication use, and ciga-
rette smoking was obtained using standard questionnaires at the
time of visit. Body mass index (BMI) was calculated by dividing the
weight in kg by the square of height in m with the participants
wearing light clothing and no shoes. Hypertension was deﬁned as
a systolic blood pressure 140 mmHg, diastolic blood pressure
90 mmHg, or antihypertensive medication use. Diabetes was
deﬁned as a fasting blood glucose >7.0mM, clinical diagnosis of
diabetes mellitus, or antidiabetic medication use.
2.6. Statistical analysis
The data were analyzed by a medical statistician using SPSS
(version 16.0; SPSS Inc., Chicago, IL, USA). The descriptive datawere
expressed as the mean ± standard deviation. After testing for a
normal distribution of variables, Student two-tail t test was used
for the comparisons between the paired and unpaired data, and
one-way analysis of variance was used for continuous variables
followed by Scheffe's test for multiple comparisons. The correlation
between two variables was assessed by Spearman correlation
analysis. Logistic regression models were used to evaluate the in-
dependent risk factors associated with the presence of angio-
graphic CAD. A two-tailed p < 0.05was considered to be statistically
signiﬁcant.
3. Results
3.1. Baseline characteristics and Lp-PLA2 levels
Baseline characteristics and Lp-PLA2 levels are shown in
Table 1. There were dramatic increases in the plasma Lp-PLA2, TG,
Table 3
Logistic regression analysis relating variables to the presence of angiographic cor-
onary artery disease.
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Age (y) 1.02 (0.97e1.07) 0.494 1.08 (0.96e1.21) 0.200
Sex 1.11 (0.86e1.21) 0.513 0.16 (0.01e2.25) 0.160
BMI 1.16 (0.97e1.39) 0.100 0.81 (0.51e1.27) 0.358
Hypertension 0.71 (0.27e1.85) 0.488 0.16 (0.01e2.17) 0.169
Diabetes 0.83 (1.01e1.94) 0.491 0.21 (0.79e2.42) 0.221
Current smoking 0.93 (0.35e2.48) 0.890 0.75 (0.16e2.12) 0.452
TC 3.72 (1.74e8.00) 0.001 2.74 (1.84e7.80) 0.015
LDL-C 2.71 (1.18e6.19) 0.018 0.329 (0.05e2.17) 0.249
HDL-C 1.86 (0.28e7.18) 1.864 0.12 (0.01e7.58) 0.340
TG 2.24 (1.05e4.76) 0.037 1.41 (0.47e4.25) 0.546
hs-CRP 1.10 (0.94e1.28) 0.238 1.17 (0.96e1.44) 0.126
Lp-PLA2 1.02 (1.01e1.02) <0.001 1.03 (1.01e1.06) 0.006
BMI ¼ body mass index; TC ¼ total cholesterol; LDL-C ¼ low density lipoprotein
cholesterol; HDL-C ¼ high density lipoprotein cholesterol; TG ¼ triglycerides;
hs-CRP ¼ high sensitivity C reactive protein; Lp-PLA2 ¼ lipoprotein associated
phospholipase A2; CI ¼ conﬁdence interval; OR ¼ odds ratio.
L. Dong et al.84TC, LDL-C, and hs-CRP levels in the CAD group compared to the
control group. No signiﬁcant differences in age, sex, current
smoking, history of hypertension or diabetes, or HDL-C were found
between the two groups.
3.2. Relationship between Lp-PLA2 and the extent of coronary
lesions
The distribution of Lp-PLA2 activity approximates a normal
distribution. According to the number of the major coronary ar-
teries with a stenosis of >50%, patients were divided into 3 groups:
one-vessel (n ¼ 38), two-vessel (n ¼ 47), and three-vessel disease
(n ¼ 39). The Lp-PLA2 levels in these groups were signiﬁcantly
higher compared to the controls. The Lp-PLA2 levels increased
slightly with the number of diseased vessels, but there was no
signiﬁcant difference among the three CAD groups (Table 2).
To assess the relationship between Lp-PLA2 and Gensini score,
patients were divided into three classes: low score (n ¼ 34), in-
termediate score (n ¼ 50), and high score (n ¼ 40). The Lp-PLA2
levels in these groups were signiﬁcantly higher compared to the
controls. The Lp-PLA2 levels increased slightly with the Gensini
score but not signiﬁcantly (Table 2).
3.3. Lp-PLA2 association with other CAD risk factors
Spearman correlation analysis revealed that the Lp-PLA2 level
was positively correlated with age (r ¼ 0.249, p ¼ 0.022), TC
(r¼ 0.326, p¼ 0.002), and LDL-C (r¼ 0.265, p¼ 0.017) but not with
BMI (r ¼ 0.114, p ¼ 0.301), sex (r¼ 0.095, p ¼ 0.387), the presence
of diabetes (r ¼ 0.042, p ¼ 0.632) or hypertension (r ¼ 0.039,
p¼ 0.726), TG (r¼ 0.130, p¼ 0.235), HDL-C (r¼ 0.044, p¼ 0.697), or
hseCRP (r ¼ 0.066, p ¼ 0.568).
3.4. Factors that correlated with the presence of angiographic CAD
Multiple logistic regression analysis was applied to identify
variables that were correlated with the presence of CAD. In uni-
variate analysis, Lp-PLA2, TC, LDL-C, and TG had higher odds ratios
in the presence of angiographic CAD, while age, sex, BMI, current
smoking, diabetes, hypertension, HDL-C, and hseCRP had lower
odds ratios (p > 0.05). In the multivariable logistic regressionmodel
after adjusting other risk factors, Lp-PLA2 and TC were indepen-
dently associated with CAD (Table 3).
4. Discussion
This study demonstrated that elevated Lp-PLA2 levels in elderly
angiographic CAD patients correlates with the traditional risk fac-
tors age, TC, and LDL-C. The presence of angiographic CAD wasTable 2
Comparison of lipoprotein-associated phospholipase A2 levels in one-, two-, and
three-vessel disease groups, different Gensini score groups with control group.
Lp-PLA2 (mg/L) ANOVA test
for trend
1-vessel disease (n ¼ 38) 347.42 ± 130.37* F ¼ 2.669
2-vessel disease (n ¼ 47) 362.69 ± 150.73** p ¼ 0.111
3-vessel disease (n ¼ 39) 365.34 ± 124.08***
Low-score group (n ¼ 34) 340.12 ± 139.42* F ¼ 2.151
Intermediate-score group (n ¼ 40) 360.14 ± 111.25* p ¼ 0.148
High-score group (n ¼ 50) 370.53 ± 135.18**
Control (n ¼ 68) 215.12 ± 58.93
*p < 0.05, **p < 0.01, and ***p < 0.001 compared to the control in one-way analysis
of variance followed by Scheffe's test.associated with Lp-PLA2 and TC levels, but there was no
evidence that Lp-PLA2 levels increased with the burden of
atherosclerosis.
The biological mechanism by which Lp-PLA2 affects the path-
ogenesis of atherosclerosis is not fully characterized. Recent evi-
dence has suggested that inﬂammation is an important
pathogenic factor in atherosclerosis and CAD, and atherosclerosis
is now recognized as a manifestation of vascular inﬂammation1e3.
Lp-PLA2, formerly called platelet-activating factor acetylhydrolase,
is an enzyme that is involved in lipoprotein metabolism and in-
ﬂammatory pathways. It is preferentially secreted by monocytes
and macrophages, which are the fundamental cells in an athero-
sclerotic plaque, and exists in the human circulation in combina-
tion with lipoprotein particles, in which approximately 80%
combine with LDL-C4. The role of Lp-PLA2 is controversial. A few
studies have argued that LP-PLA2 is an antiatherosclerosis enzyme
that degrades platelet activating factor and related phospho-
lipids13, while others have suggested that Lp-PLA2 is proathero-
genic. Its proatherogenic role is thought to be related to the
hydrolysis of oxidized LDL to produce the proinﬂammatory me-
diators lysophosphatidylcholine and oxidized free fatty acid4,
which can stimulate the secretion of cytokines from macrophages
and promote plaque development.
Previous studies have revealed that serum Lp-PLA2 is signiﬁ-
cantly increased in patients with coronary endothelial dysfunction,
which is recognized as an early stage of atherosclerosis14. It was
remarkably expressed in human and rabbit atherosclerotic lesions,
especially in the necrotic core of vulnerable plaques and sur-
rounding macrophages15. A similar phenomenon was reported
among symptomatic patients who suffered from carotid artery
plaque, a marker of atherosclerotic disease16,17. Most studies have
examined the association between the Lp-PLA2 level and the extent
of CAD assessed by coronary angiography and found that Lp-PLA2
was associated with the severity of angiographic CAD in uni-
variable analyses18e21. The association persisted after adjustment in
some studies19e21 but was no longer signiﬁcant in one study18. Lp-
PLA2 levels in CAD patients were also related to the stability of
atherosclerotic plaques and were independently associated with
plaque rupture22. Many large population-based studies have
demonstrated that high Lp-PLA2 levels are associated with a high
frequency of cardiovascular events6e8. These studies have provided
powerful evidence to support the notion that Lp-PLA2 is crucial in
plaque progression and demonstrated that increased Lp-PLA2
Lp-PLA2 Associated with Angiographic CAD 85levels are involved in the process of atherosclerosis initiation and
development and even coronary events.
Although Lp-PLA2 has been found to be a potential biomarker of
CAD risk in the elderly9e11, as far as we know, there is no study that
has investigated the association of Lp-PLA2 with angiographic CAD
and lesion severity in the elderly. Plaque morphology may change,
and atherosclerotic burden may increase with age. Thus, the asso-
ciation of Lp-PLA2 with CAD may likewise vary with age. We
therefore examined the association of Lp-PLA2 with angiographic
CAD in the elderly. Our result was consistent with the above
studies18e21, which we found that Lp-PLA2 levels in CAD patients
were also signiﬁcantly higher, and Lp-PLA2was still associatedwith
the presence of CAD even after adjusting for traditional CAD risk
factors. Our study extended the predictive value of Lp-PLA2 to the
elderly and underscored the importance of Lp-PLA2 as a cardio-
vascular risk factor in the elderly. In contrast to the above studies,
our study failed to ﬁnd a correlation between Lp-PLA2 and the
degree of coronary artery lesions, even though Lp-PLA2 increased
slightly as the number of disease coronary artery branches and
Gensini score increased. One possible reason for this difference is
an important limitation in our study, which was a relatively small
sample size that could prevent the result from reaching statistical
signiﬁcance. Another possible reason is that most of our patients
received lipid-lowering therapy (data no shown) before the study.
One study has demonstrated that lipid-lowering therapy had a
pronounced effect on Lp-PLA2, and only when restricted to in-
dividuals not using lipid-lowering drugs was Lp-PLA2 associated
with CAD severity and the number of diseased coronary vessels
with signiﬁcant stenosis19.
We also noted strong correlations between Lp-PLA2 and age,
TC, and LDL-C, which is consistent with the published data10,19.
The correlations between Lp-PLA2 and TC and LDL-C were ex-
pected because approximately 80% of Lp-PLA2 is bound to LDL-C
and another 7% to very low-density lipoprotein cholesterol.
Because Lp-PLA2 and hs-CRP have been reported to be com-
plementary in risk prediction, we also investigated the role of
hs-CRP and failed to ﬁnd a relationship with Lp-PLA2. Although
hs-CRP was higher in the CAD group, multivariate models
showed that Lp-PLA2 was an important predictor of the pres-
ence of CAD, while hs-CRP was not. These differences suggest
that the importance of hs-CRP as a risk factor may decrease with
increasing age, which is consistent with a previous study23, or
hs-CRP may affect the atherosclerotic process through patho-
physiological mechanisms other than Lp-PLA2 in the elderly.
Furthermore, a previous study found that hs-CRP tends to be
elevated in patients with a wide range of inﬂammatory condi-
tions; however, it has limitations as a speciﬁc marker for CAD24.
Unlike hs-CRP, the Lp-PLA2 concentration has been shown to be
stable over time and not affected by systemic inﬂammation25.
Thus, Lp-PLA2 appears to be a key mediator prior to hs-CRP for
predicting atherosclerosis and CAD in the elderly. This result
supports further exploration of the role of Lp-PLA2 in identifying
older individuals at risk for atherosclerosis and CAD.
Atherosclerosis remains the leading cause of death, myocardial
infarction, and stroke, and its incidence continues to increase
despite aggressive evidence-based standard treatment. This has
prompted research directed at reducing the atherosclerotic burden
and improving the stability of vulnerable plaques to reduce car-
diovascular risk. Lp-PLA2 has a dramatic role in promoting the
formation of atherosclerosis and predicting the incidence of coro-
nary heart disease and severity of coronary artery lesions.
Furthermore, animal and human studies have shown that taking
oral medications that selectively inhibit Lp-PLA2 can reduce plasma
Lp-PLA2 activity and stabilize the necrotic core volume26,27. Thus,
Lp-PLA2 may be a new target for controlling CAD and represent apromising approach in the future, especially for the elderly who
have a poor tolerance for invasive treatments.5. Conclusion
Lipoprotein-associated phospholipase A2 was conﬁrmed as a
risk factor for CAD and independently predicts the presence of
angiographic CAD in the elderly.
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